Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab plus chemotherapy in early-stage ER+/HER2- breast cancer
NCT03725059Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Dec 2018
- Primary completion
- Jan 2031
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 3, randomised, double-blind trial in estrogen receptor-positive breast cancer (ER+) comparing Pembrolizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoints: Pathological Complete Response Rate (ypT0/Tis ypN0) and Event-Free Survival up to 12 years. Started Dec 2018; status: active, not recruiting.
02
Drugs
03
Conditions
estrogen receptor-positive breast cancer (ER+)
Beyond the preview
Go deeper on NCT03725059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03725059.